Identification of Gene Markers Associated With Aggressive Meningioma by Filtering Across Multiple Sets of Gene Expression Arrays

Stuart, Jourdan E.; Lusis, Eriks A.; Scheck, Adrienne C.; Coons, Stephen W.; Lal, Anita; Perry, Arie; Gutmann, David H.

doi:10.1097/nen.0b013e3182018f1c

Cited by 46 publications

(38 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, Sox11 might also be of potential value as a diagnostic marker of neoplastic astrocytes. A similar absence of correlation between Sox11 expression and histological grade has been noted in ovarian carcinoma (Sernbo et al , 2011), as opposed to meningiomas where marked upregulation of Sox11 mRNA has been observed in grade III (Stuart et al , 2011). …”

Section: Discussionsupporting

confidence: 58%

Sox11 expression in astrocytic gliomas: correlation with nestin/c-Met/IDH1-R132H expression phenotypes, p-Stat-3 and survival

Korkolopoulou¹,

Levidou²,

El-Habr³

et al. 2013

Br J Cancer

View full text Add to dashboard Cite

Background:Sox11 is a transcription factor expressed in foetal and neoplastic brain tissue, including gliomas. It has been shown to suppress the tumourigenicity of glioma stem cells in vivo, thereby being hypothesised to function as a tumour suppressor.Methods:We investigated the expression of Sox11 in 132 diffuse astrocytomas in relation to the regulator cell marker nestin, c-Met and IDH1-R132H, which have shown to be differentially expressed among the molecular subgroups of malignant gliomas, as well as to an inducer of astrocytic differentiation, that is, signal transducer and activator of transcription (p-STAT-3), clinicopathological features and survival.Results:Sox11 immunoreactivity was identified in all tumours irrespective of grade, but being correlated with p-STAT-3. Three out of seven cases showed partial Sox11 promoter methylation. In >50% of our cases neoplastic cells coexpressed Sox11 and nestin, a finding further confirmed in primary glioblastoma cell cultures. Furthermore, nestin, c-Met and IDH1-R132H expression differed among grade categories. Cluster analysis identified four groups of patients according to c-Met, nestin and IDH1-R132H expression. The c-Met/nestin high-expressor group displayed a higher Sox11 expression. Sox11 expression was an indicator of favourable prognosis in glioblastomas, which remained in multivariate analysis and validated in an independent set of 72 cases. The c-Met/nestin high-expressor group was marginally with shorter survival in univariate analysis.Conclusions:We highlight the importance of Sox11 expression as a favourable prognosticator in glioblastomas. c-Met/nestin/IDH1-R132H expression phenotypes recapitulate the molecular subgroups of malignant glioma.

show abstract

Section: Discussionsupporting

confidence: 58%

Sox11 expression in astrocytic gliomas: correlation with nestin/c-Met/IDH1-R132H expression phenotypes, p-Stat-3 and survival

Korkolopoulou¹,

Levidou²,

El-Habr³

et al. 2013

Br J Cancer

View full text Add to dashboard Cite

show abstract

“…We found that transcript levels for DLG7 and TOP2A were highly correlated and suggest that DLGAP5 gene transcription should be further studied for its potential as predictor of outcome in high-risk CaP. Of note, overexpression of transcripts for TOP2A and DLG7 has been recently identified in grade III meningioma in comparison to grade I meningioma [37]. This information adds value to the notion that co-expression of TOP2A and DLG7 is relevant in tumorigenesis and should be further explored in the search of biomarkers for advanced disease.…”

Section: Discussionmentioning

confidence: 91%

Prognostic Value of Discs Large Homolog 7 Transcript Levels in Prostate Cancer

et al. 2013

View full text Add to dashboard Cite

Hypoxia has been associated with malignant progression, metastasis and resistance to therapy. Hence, we studied expression of hypoxia–regulated genes in 100 prostate cancer (CaP) bulk tissues and 71 adjacent benign tissues. We found 24 transcripts significantly overexpressed (p≤0.02). Importantly, higher transcript levels of disc large (drosophila) homolog-associated protein 5 (DLGAP5)/discs large homolog 7 (DLG7)/hepatoma up-regulated protein (HURP), hyaluronan-mediated motility receptor (HMMR) and cyclin B1 (CCNB1) were associated with higher Gleason score and more advanced systemic progression. Since the products of HMMR and CCNB1 have been identified recently as molecular markers of CaP progression, we postulated that DLG7 has prognostic value too. To test this hypothesis, we measured transcript levels for DLG7 in a 150-pair case-control cohort. The cases (progression to systemic disease within six years of surgery) and controls (no progression within eight years) were matched for clinical and pathologic prognostic variables, including grade, stage, and preoperative serum levels of PSA. The overall prognostic ability of DLG7, as tested in receiver operating characteristic analysis was of 0.74 (95% CI, 0.68 to 0.8). Overall, our data indicate that expression of DLG7, a hypoxia-controlled gene, holds prognostic potential in high-risk CaP; this also demonstrates that variation of oxygen tension may constitute a tool for identification of novel biomarkers for CaP.

show abstract

“…In cancer biology, TPX2 was initially recognized as an oncogene factor amplified from chromosome 20q11.2 (12). Several studies have demonstrated that TPX2-induced tumor proliferation and inhibition of apoptosis, was upregulated in various tumorous tissue types, including lung, ovarian, pancreatic, breast and oral cancer (2,3,6,(13)(14)(15)(16)(17)(18)(19)(20).…”

Section: Discussionmentioning

confidence: 99%

TPX2 regulates tumor growth in human cervical carcinoma cells

Jiang

Shen

Xuerui

et al. 2014

Molecular Medicine Reports

View full text Add to dashboard Cite

Abstract. The targeting protein for the Xenopus kinesin-like protein 2 (TPX2), a microtubule-associated protein, has been utilized as a tool to evaluate, more precisely, the proliferative behavior of tumor cells. The abnormal expression of TPX2 in a variety of malignant tumor types has been reported, however less is known about its role in cervical cancer. In the present study, the association between TPX2 expression and the biological behavior of cervical cancer, was investigated. Immunohistochemistry and RT-PCR were used to detect the expression of TPX2 in cervical cancer tissues. The inhibitory effect of TPX2-siRNA on the growth of SiHa human cervical carcinoma cells was studied in vitro. TPX2 expression was identified as significantly higher in cervical carcinoma compared with the control, normal cervical tissues. TPX2 siRNA transfected into SiHa cells induced apoptosis and inhibited cell proliferation and invasion. Similar results were obtained by in vivo transplantation, as TPX2 siRNA transfection significantly reduced tumor growth of the xenograft in nude mice. The results demonstrated that TPX2 is important in the regulation of tumor growth in cervical cancer and therefore may be a potential therapeutic target as a novel treatment strategy. IntroductionTargeting protein for Xenopus kinesin-like protein 2 (TPX2) is a microtubule-associated protein. It is one of the best-known factors regulated by the RanGTP gradient and has a functional role in mitosis. The appearance and subsequent expression of TPX2 is mediated by the cell cycle, emerging at G1-S stage and diminishing following the completion of cytokinesis (1).In recent studies, it has been revealed that TPX2 is overexpressed in various carcinoma tissue types, including lung (2), breast (3) and salivary gland cancer (4). In this study, it was demonstrated that the overexpression of TPX2 in tumor cells caused exuberant amplification of the centrosome, developed aneuploidy and transformation, promotion of tumor proliferation and differentiation, as well as downregulation of tumor apoptosis (2-6). Conversely, it has also been demonstrated that inhibiting TPX2 and its associated pathways in tumor cells, leads to cancer cell apoptosis. This provides evidence that TPX2 may be a potential therapeutic candidate for the development of novel pharmacological cancer treatments (5,7,8).One recent study suggested that TPX2 may also be expressed in cervical carcinoma (8), however the exact function of TPX2 in cervical cancer formation and regulation remains elusive. In the present study, the expression of TPX2 in cervical carcinoma in human patients and the human cervical cancer cell line SiHa cells was examined. Gene-silencing methods were utilized to specifically knock-down TPX2 expression in vitro and in vivo, to advance the understanding of the regulatory mechanisms of TPX2 in cervical cancer development. Our results may provide invaluable experimental data, to facilitate in the diagnosis and treatment of cervical cancer in the future. Materials and methodsClinic...

show abstract

Identification of Gene Markers Associated With Aggressive Meningioma by Filtering Across Multiple Sets of Gene Expression Arrays

Cited by 46 publications

References 37 publications

Sox11 expression in astrocytic gliomas: correlation with nestin/c-Met/IDH1-R132H expression phenotypes, p-Stat-3 and survival

Sox11 expression in astrocytic gliomas: correlation with nestin/c-Met/IDH1-R132H expression phenotypes, p-Stat-3 and survival

Prognostic Value of Discs Large Homolog 7 Transcript Levels in Prostate Cancer

TPX2 regulates tumor growth in human cervical carcinoma cells

Contact Info

Product

Resources

About